Stephanie M Fukui1, Damani A Piggott2,3, Kristine M Erlandson4,5. 1. School of Medicine, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA. 2. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 3. Department of Epidemiology, Johns Hopkins University School of Public Health, Baltimore, MD, USA. 4. School of Medicine, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA. Kristine.erlandson@ucdenver.edu. 5. Department of Medicine, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA. Kristine.erlandson@ucdenver.edu.
Abstract
PURPOSE OF REVIEW: As a consequence of antiretroviral therapy, the proportion of older HIV-infected adults is increasing, with a concomitant shift in burden of illness to age-related syndromes and disease. Frailty is an age-related syndrome of increased vulnerability to stress, predictive of major adverse clinical outcomes among HIV-infected and uninfected persons alike. Understanding frailty pathogenesis is critical to developing interventions to improve health outcomes in HIV. Here, we review the current evidence for the relationship between inflammation and frailty in HIV, and the potential for novel, inflammation-targeted interventions. RECENT FINDINGS: Dysregulated inflammation has been consistently associated with frailty in elderly HIV-uninfected persons. Dysregulated inflammation is also central to HIV pathophysiology and several recent studies have demonstrated the important association of inflammation with frailty in HIV. Some evidence suggests that anti-inflammatory therapies may be effective in ameliorating the adverse impact of frailty among aging HIV-infected adults, though further investigation is necessary. Inflammation has been implicated in frailty in HIV infection, and improved understanding of the role that inflammation plays in frailty pathogenesis is key to the development of effective therapies to slow or prevent frailty in the vulnerable HIV-infected population.
PURPOSE OF REVIEW: As a consequence of antiretroviral therapy, the proportion of older HIV-infected adults is increasing, with a concomitant shift in burden of illness to age-related syndromes and disease. Frailty is an age-related syndrome of increased vulnerability to stress, predictive of major adverse clinical outcomes among HIV-infected and uninfected persons alike. Understanding frailty pathogenesis is critical to developing interventions to improve health outcomes in HIV. Here, we review the current evidence for the relationship between inflammation and frailty in HIV, and the potential for novel, inflammation-targeted interventions. RECENT FINDINGS: Dysregulated inflammation has been consistently associated with frailty in elderly HIV-uninfected persons. Dysregulated inflammation is also central to HIV pathophysiology and several recent studies have demonstrated the important association of inflammation with frailty in HIV. Some evidence suggests that anti-inflammatory therapies may be effective in ameliorating the adverse impact of frailty among aging HIV-infected adults, though further investigation is necessary. Inflammation has been implicated in frailty in HIV infection, and improved understanding of the role that inflammation plays in frailty pathogenesis is key to the development of effective therapies to slow or prevent frailty in the vulnerable HIV-infected population.
Entities:
Keywords:
Antiretroviral therapy; Dysregulated inflammation; Frailty pathogenesis; HIV infection; Inflammation
Authors: Kristine M Erlandson; Amanda A Allshouse; Catherine M Jankowski; Eric J Lee; Kevin M Rufner; Brent E Palmer; Cara C Wilson; Samantha MaWhinney; Wendy M Kohrt; Thomas B Campbell Journal: J Infect Dis Date: 2013-04-04 Impact factor: 5.226
Authors: Jason M Brenchley; David A Price; Timothy W Schacker; Tedi E Asher; Guido Silvestri; Srinivas Rao; Zachary Kazzaz; Ethan Bornstein; Olivier Lambotte; Daniel Altmann; Bruce R Blazar; Benigno Rodriguez; Leia Teixeira-Johnson; Alan Landay; Jeffrey N Martin; Frederick M Hecht; Louis J Picker; Michael M Lederman; Steven G Deeks; Daniel C Douek Journal: Nat Med Date: 2006-11-19 Impact factor: 53.440
Authors: Janet P Tate; Amy C Justice; Michael D Hughes; Fabrice Bonnet; Peter Reiss; Amanda Mocroft; Jacob Nattermann; Fiona C Lampe; Heiner C Bucher; Timothy R Sterling; Heidi M Crane; Mari M Kitahata; Margaret May; Jonathan A C Sterne Journal: AIDS Date: 2013-02-20 Impact factor: 4.177
Authors: Heather M Derry; Carrie D Johnston; Chelsie O Burchett; Mark Brennan-Ing; Stephen Karpiak; Yuan-Shan Zhu; Eugenia L Siegler; Marshall J Glesby Journal: J Gerontol B Psychol Sci Soc Sci Date: 2022-01-12 Impact factor: 4.077
Authors: Stephanie M Dillon; Mona H Abdo; Melissa P Wilson; Jay Liu; Catherine M Jankowski; Charles E Robertson; Yunus Tuncil; Bruce Hamaker; Daniel N Frank; Samantha MaWhinney; Cara C Wilson; Kristine M Erlandson Journal: AIDS Res Hum Retroviruses Date: 2021-04-30 Impact factor: 1.723
Authors: Nicholas Rhoades; Norma Mendoza; Allen Jankeel; Suhas Sureshchandra; Alexander D Alvarez; Brianna Doratt; Omeid Heidari; Rod Hagan; Brandon Brown; Steven Scheibel; Theodore Marbley; Jeff Taylor; Ilhem Messaoudi Journal: Front Immunol Date: 2019-03-12 Impact factor: 7.561
Authors: Jehad Alzahrani; Tabinda Hussain; David Simar; Riya Palchaudhuri; Mohamed Abdel-Mohsen; Suzanne M Crowe; George W Mbogo; Clovis S Palmer Journal: EBioMedicine Date: 2019-07-18 Impact factor: 8.143
Authors: Karen Nieves-Lugo; Deanna Ware; Keri Althoff; Mark Brennan-Ing; Steven Meanley; Andre L Brown; Sabina A Haberlen; Mary Masters; James E Egan; Mackey R Friedman; Michael Plankey Journal: Innov Aging Date: 2021-09-03
Authors: Kevin Wong; James Nguyen; Lillie Blair; Marina Banjanin; Bunraj Grewal; Shane Bowman; Hailey Boyd; Grant Gerstner; Hyun Jun Cho; David Panfilov; Cho Ki Tam; Delaney Aguilar; Vishwanath Venketaraman Journal: J Clin Med Date: 2020-11-06 Impact factor: 4.241
Authors: Eveline Verheij; Ferdinand W Wit; Sebastiaan O Verboeket; Maarten F Schim van der Loeff; Jeannine F Nellen; Peter Reiss; Gregory D Kirk Journal: J Acquir Immune Defic Syndr Date: 2021-01-01 Impact factor: 3.771